Fountzilas George, Psyrri Amanda, Giannoulatou Eleni, Tikas Ioannis, Manousou Kyriaki, Rontogianni Dimitra, Ciuleanu Elisabeta, Ciuleanu Tudor, Resiga Liliana, Zaramboukas Thomas, Papadopoulou Kyriaki, Bobos Mattheos, Chrisafi Sofia, Tsolaki Eleftheria, Markou Konstantinos, Giotakis Evangelos, Koutras Angelos, Psoma Elsa, Kalogera-Fountzila Anna, Skondra Maria, Bamia Christina, Pectasides Dimitrios, Kotoula Vassiliki
Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Int J Cancer. 2018 Jan 1;142(1):66-80. doi: 10.1002/ijc.31023. Epub 2017 Sep 30.
Genomic patterns of nasopharyngeal carcinomas (NPCs) have as yet been studied in Southeast Asian (SEA) patients. Here, we investigated genomic patterns of locally advanced NPC Southeast European (SEE) patients treated with chemoradiotherapy. We examined 126 tumors (89% EBV positive) from Greek and Romanian NPC patients with massively parallel sequencing. Paired tumor-cell-rich (TC) and infiltrating-lymphocyte-rich (TILs) samples were available in 19 and paired tumor-germline samples in 68 cases. Top mutated genes were BRCA1 (54% of all tumors); BRCA2 (29%); TP53 (22%); KRAS (18%). Based on the presence and number of mutations and mutated genes, NPC were classified as stable (no mutations, n = 27); unstable (>7 genes with multiple mutations, all BRCA1 positive, n = 21); and of intermediate stability (1-7 singly mutated genes, n = 78). BRCA1 p.Q563* was present in 59 tumors (48%), more frequently from Romanian patients (p < 0.001). No pathogenic germline mutations were identified. NPC exhibited APOBEC3A/B and nucleotide-excision-repair-related mutational signatures. As compared to TC, TILs demonstrated few shared and a higher number of low frequency private mutations (p < 0.001). In multivariate analysis models for progression-free survival, EBV positivity was a favorable prognosticator in stable tumors; BRCA1 mutations were unfavorable only in tumors of intermediate stability. In conclusion, other than described for SEA NPC, somatic BRCA1 mutations were common in SEE NPC; these were shared between TC and TILs, and appeared to affect patient outcome according to tumor genomic stability status. Along with the identified mutational signatures, these novel data may be helpful for designing new treatments for locally advanced NPC.
尚未对东南亚(SEA)患者的鼻咽癌(NPC)基因组模式进行研究。在此,我们调查了接受放化疗的东南欧(SEE)局部晚期NPC患者的基因组模式。我们通过大规模平行测序检查了126例来自希腊和罗马尼亚NPC患者的肿瘤(89%为EBV阳性)。19例患者可获得配对的富含肿瘤细胞(TC)和富含浸润淋巴细胞(TILs)的样本,68例患者可获得配对的肿瘤-种系样本。最常发生突变的基因是BRCA1(占所有肿瘤的54%);BRCA2(29%);TP53(22%);KRAS(18%)。根据突变和突变基因的存在情况及数量,NPC被分为稳定型(无突变,n = 27);不稳定型(>7个基因有多个突变,均为BRCA1阳性,n = 21);以及中等稳定型(1 - 7个单突变基因,n = 78)。BRCA1 p.Q563*存在于59个肿瘤中(48%),在罗马尼亚患者中更常见(p < 0.001)。未发现致病的种系突变。NPC表现出APOBEC3A/B和核苷酸切除修复相关的突变特征。与TC相比,TILs显示出很少的共享突变和更多数量的低频私人突变(p < 0.001)。在无进展生存期的多变量分析模型中,EBV阳性在稳定型肿瘤中是一个有利的预后指标;BRCA1突变仅在中等稳定型肿瘤中是不利的。总之,除了SEA NPC所描述的情况外,体细胞BRCA1突变在SEE NPC中很常见;这些突变在TC和TILs之间共享,并且似乎根据肿瘤基因组稳定性状态影响患者的预后。连同已确定的突变特征,这些新数据可能有助于设计针对局部晚期NPC的新治疗方法。